Viral transduction for T cell engineering in immunotherapy
Abstract
Viral transduction of primary T cells enables stable genetic engineering for research and immunotherapy, supporting both transgene overexpression and gene deletion. Although the overall workflow can be similar to transduction in other mammalian cell lines, primary T cell culture imposes distinct requirements such as cell-state-dependent nuances shaped by T cell activation and proliferation, which can make it challenging to obtain a sufficient number of genetically engineered T cells. This article provides practical guidance for researchers new to T cells but familiar with basic mammalian cell culture.
Fields of Study & Subjects
CAR-T cell therapy research
Virus-based gene therapy research
CRISPR and Genetic Engineering
Publication details
- Journal / source
- Molecules and Cells
- Volume
- 49
- Issue
- 2
- Pages
- 100311–100311
- Publication date
- 4 January 2026
- Language
- EN